Although patients in the intermediate prognosis group can either receive chemotherapy or allo‐HSCT for consolidation according to AML guidelines, our data suggested that PHF6 may be related to poor prognosis and that it may be better to perform allo‐HSCT for PHF6mutAML patients assigned to the intermediate prognosis group. Here, PHF6 is linked to acute myeloid leukemia.